Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HyBryte and Visible Light in Mycosis Fungoides
NCT05872854Phase 2Completed
- Start
- Aug 2023
- Primary completion
- Dec 2025
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hypericin in mycosis fungoides (MF). Primary endpoint: Number of Treatment Responses of Index Lesions at 54 weeks. Started Aug 2023; status: completed.
02
Drugs
hypericin
03
Conditions
mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT05872854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05872854.